Zobrazeno 1 - 10
of 183
pro vyhledávání: '"Marcel O. Bonn-Miller"'
Publikováno v:
Biomedicines, Vol 12, Iss 7, p 1551 (2024)
Cannabielsoin (CBE) is primarily recognized as an oxidation byproduct of cannabidiol (CBD) and a minor mammalian metabolite of CBD. The pharmacological interactions between CBE and cannabinoid receptors remain largely unexplored, particularly with re
Externí odkaz:
https://doaj.org/article/dbcb16ea056b4660912088d736fc1d13
Autor:
Mehdi Haghdoost, Scott Young, Alisha K. Holloway, Matthew Roberts, Ivori Zvorsky, Marcel O. Bonn-Miller
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 14, p 7724 (2024)
Phytocannabinoids with seven-carbon alkyl chains (phorols) have gained a lot of attention, as they are commonly believed to be more potent versions of typical cannabinoids with shorter alkyl chains. At the time of this article, cannabidiphorol (CBDP)
Externí odkaz:
https://doaj.org/article/18d3c502e23545a08406b686b23da810
Autor:
Mehdi Haghdoost, Yossef López de los Santos, Megan Brunstetter, Morgan L. Ferretti, Matthew Roberts, Marcel O. Bonn-Miller
Publikováno v:
Pharmaceuticals, Vol 17, Iss 5, p 637 (2024)
Even slight structural differences between phytocannabinoid isomers are usually enough to cause a change in their biological properties. In this study, we used in vitro CB1 agonism/antagonism assays to compare the receptor binding functionality of TH
Externí odkaz:
https://doaj.org/article/1967a2bebcee41a896daf348a33b80d6
Autor:
Erica N. Peters, Helena Yardley, Amy Harrison, Graham M.L. Eglit, Jose Antonio, Cynthia Turcotte, Marcel O. Bonn-Miller
Publikováno v:
Journal of the International Society of Sports Nutrition, Vol 20, Iss 1 (2023)
ABSTRACTBackground Cannabinoid-containing products are marketed to athletes as promoting recovery, in spite of a lack of data on their safety and effects. This randomized, double-blind, placebo-controlled, repeated-dose pilot study tested the safety,
Externí odkaz:
https://doaj.org/article/0955398cc3024183a7441ef4a64b844e
Autor:
Erin L. Martin, Justin C. Strickland, Nicolas J. Schlienz, Joel Munson, Heather Jackson, Marcel O. Bonn-Miller, Ryan Vandrey
Publikováno v:
Frontiers in Psychiatry, Vol 12 (2021)
Background: Anxiety and depressive disorders are highly prevalent. Patients are increasingly using medicinal cannabis products to treat these disorders, but little is known about the effects of medicinal cannabis use on symptoms of anxiety and depres
Externí odkaz:
https://doaj.org/article/5a75b60804e24717b5a5829c3051fec9
Autor:
Helen Heussler, Jonathan Cohen, Natalie Silove, Nancy Tich, Marcel O. Bonn-Miller, Wei Du, Carol O’Neill, Terri Sebree
Publikováno v:
Journal of Neurodevelopmental Disorders, Vol 11, Iss 1, Pp 1-9 (2019)
Abstract Background Fragile X syndrome (FXS) is characterized by a range of developmental, neuropsychiatric, and behavioral symptoms that cause significant impairment in those with the disorder. Cannabidiol (CBD) holds promise as a potential treatmen
Externí odkaz:
https://doaj.org/article/3b5a2d811d91482ebf1a0edc66cee477
Autor:
Joshua A. Lile, Brian W. Turner, David H. Cox, Marcel O. Bonn-Miller, Ned R. Katz, Thomas P. Shellenberg, William W. Stoops, Justin C. Strickland
Publikováno v:
Journal of Addiction Medicine. 17:e87-e93
Autor:
Laura MacNair, Irina Mosesova, Jonathon C. Arnold, Maia G. Etchart, Lyndsey L. Anderson, M Hunter Land, Marcel O. Bonn-Miller
Publikováno v:
Cannabis Cannabinoid Res
INTRODUCTION: Legalization of medicinal cannabis around the world has led to an increase in the use of commercial cannabis-based products in the community. These cannabis-based products are being used in combination with conventional drugs to treat a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Megan Brunstetter, Alex Simonian, Kimberly A. Babson, Mallory J E Loflin, Hal S. Wortzel, Ryan Vandrey, Marcel O. Bonn-Miller
Publikováno v:
Cannabis Cannabinoid Res
INTRODUCTION: Given the increasing availability and use of cannabis among individuals with post-traumatic stress disorder (PTSD) and the addition of PTSD as an eligible diagnosis in several U.S. medical cannabis programs, the efficacy of dispensary-o